Table 5.
Basic information of extracted patients from SEER diagnosed in 2010–2015 after propensity–score matching
| Variables | Total | Early-onset SRCC | Late-onset SRCC | P value |
|---|---|---|---|---|
| Total | 464 | 232 | 232 | |
| Sex | 0.925 | |||
| Male | 189 (40.73%) | 94 (40.52%) | 95 (40.95%) | |
| Female | 275 (59.27%) | 138 (59.48%) | 137 (59.05%) | |
| Race | 0.522 | |||
| White | 310 (66.81%) | 156 (67.24%) | 154 (66.38%) | |
| Black | 58 (25%) | 32 (13.79%) | 26 (11.21%) | |
| Other | 96 (20.69%) | 44 (18.97%) | 52 (22.41%) | |
| Primary site | 0.074 | |||
| Cardia | 54 (11.64%) | 20 (8.62%) | 34 (14.66%) | |
| Fundus | 16 (6.9%) | 7 (3.02%) | 9 (3.88%) | |
| Antrum | 250 (53.88%) | 118 (50.86%) | 132 (56.9%) | |
| Body | 66 (14.22%) | 39 (16.81%) | 27 (11.64%) | |
| Overlappping/NOS | 78 (16.81%) | 48 (20.69%) | 30 (12.93%) | |
| T stage | 0.909 | |||
| Tis/T1 | 87 (18.75%) | 44 (18.96%) | 43 (18.53%) | |
| T2 | 64 (13.79%) | 30 (12.93%) | 34 (14.66%) | |
| T3 | 149 (32.11%) | 73 (31.47%) | 76 (32.76%) | |
| T4 | 164 (70.69%) | 85 (36.64%) | 79 (34.05%) | |
| N stage | 0.981 | |||
| N0 | 169 (36.42%) | 84 (36.21%) | 85 (36.64%) | |
| N1 | 71 (15.3%) | 37 (15.95%) | 34 (14.66%) | |
| N2 | 90 (19.4%) | 44 (18.97%) | 46 (19.83%) | |
| N3 | 134 (28.88%) | 67 (28.88%) | 67 (28.88%) | |
| M stage | 0.011 | |||
| M0 | 399 (86%) | 190 (80.34%) | 209 (89.66%) | |
| M1 | 65 (14%) | 42 (19.66%) | 23 (10.34%) | |
| Tumor number | 1 | |||
| 1 | 431 (92.89%) | 215 (92.68%) | 216 (93.1%) | |
| > 1 | 33 (7.11%) | 17 (7.32%) | 16 (6.9%) | |
| Tumor size | 0.926 | |||
| ≤ 2 cm | 102 (21.98%) | 50 (21.55%) | 52 (22.41%) | |
| ≤ 5 cm | 174 (37.5%) | 89 (38.36%) | 85 (36.64%) | |
| > 5 cm | 188 (40.52%) | 93 (40.09%) | 95 (40.95%) | |
| Examined LNs | 0.641 | |||
| ≤ 16 | 213 (45.91%) | 104 (44.87%) | 109 (49.06%) | |
| > 16 | 251 (54.09%) | 128 (55.13%) | 123 (50.94%) | |
| Chemotherapy | 0.849 | |||
| No | 182 (39.22%) | 90 (38.79%) | 92 (39.66%) | |
| Yes | 282 (60.78%) | 142 (61.21%) | 140 (60.34%) |